financetom
Business
financetom
/
Business
/
SoftBank revises loss estimate to $8.4 billion for FY20 due to WeWork write-down
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
SoftBank revises loss estimate to $8.4 billion for FY20 due to WeWork write-down
Apr 30, 2020 1:10 AM

The troubled SoftBank Group has had to revise it loss forecast for the year ending March 2020 due to a write-down on investments in WeWork, just days after it had put out the results forecast, in which the Japanese company had indicated losses for the first time in 15 years.

The company had brought out forecasts for the fiscal year earlier this month on April 13 and is set to announce its earnings for the year on May 18.

On Thursday, SoftBank put out a release citing revision of results forecast, in which the group said that it now estimates a higher net loss of 900 billion Yen, or $8.4 billion, compared to the previous forecast of 750 billion Yen.

The company said non-operating losses will touch 1 trillion Yen, of which 700 billion Yen will be attributable to WeWork.

"These non-operating losses were previously expected to total approximately JPY 800 billion, however they are currently expected to total more than JPY 1 trillion. Of this, approximately JPY 700 billion loss is attributable to the investment, loan commitment, and financial guarantee contract in favor of WeWork,” SoftBank said in the release.

Softbank maintained its operating loss. On April 13, SoftBank forecast a 1.35 trillion yen ($12.5 billion) operating loss for FY20 and 1.8 trillion yen loss from its Vision Fund.

“The difference in operating income is mainly attributable to the expected recording of investment loss of approximately JPY 1.8 trillion at SoftBank Vision Fund for fiscal 2019, resulting from a decrease in the fair value of investments due to the deteriorating market environment,” the company had said.

“The difference in income before income tax is mainly due to the expected recording of non-operating loss totaling approximately JPY 800 billion for fiscal 2019 on investments held outside of SoftBank Vision Fund, including The We Company (WeWork) and WorldVu Satellites Limited (OneWeb),” SoftBank had said.

This is first time in 15 years SoftBank expects to see a net loss. In FY19, SoftBank saw a profit of 1.4 trillion Yen.

SoftBank had invested over $13 billion into WeWork, but following troubles at the company, SoftBank also pulled out of its $3 billion bailout plan for the startup, thus getting into a legal battle.

First Published:Apr 30, 2020 10:10 AM IST

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Steven Madden to cut sourcing from China on tariff worries under Trump
Steven Madden to cut sourcing from China on tariff worries under Trump
Nov 9, 2024
Nov 7 (Reuters) - Steven Madden executives said on Thursday the company was working quickly to shift product sourcing out of China to other countries after Donald Trump's U.S. presidential election victory. In February, Trump said if he came to power, he would impose tariffs on China again, which could exceed 60%, putting a lot of strain on retail companies...
Wheels Up Experience Pares Net Loss in Q3, Revenue Falls; Shares Advance
Wheels Up Experience Pares Net Loss in Q3, Revenue Falls; Shares Advance
Nov 9, 2024
11:36 AM EST, 11/07/2024 (MT Newswires) -- Wheels Up Experience ( UP ) shares advanced 0.5% in recent Thursday trading after the private aviation services company significantly narrowed its Q3 net loss year over year. The company reported a Q3 net loss of $0.08 per diluted share, compared with a loss of $3.51 a year earlier. Revenue for the quarter...
Mustang Bio Gets FDA Orphan Drug Designation for MB-108 in Malignant Glioma Treatment
Mustang Bio Gets FDA Orphan Drug Designation for MB-108 in Malignant Glioma Treatment
Nov 9, 2024
11:34 AM EST, 11/07/2024 (MT Newswires) -- Mustang Bio ( MBIO ) said Thursday that MB-108, an oncolytic virus currently undergoing phase 1 clinical trial for malignant glioma treatment, has been granted orphan drug designation by the US Food and Drug Administration. The designation provides MB-108 seven years of market exclusivity in the US for the treatment. Mustang also said...
Canada Goose Beats Q2 Estimates, Company Warns Of 'Increased Pressure' On Luxury Consumer Spending
Canada Goose Beats Q2 Estimates, Company Warns Of 'Increased Pressure' On Luxury Consumer Spending
Nov 9, 2024
Canada Goose Holdings Inc. ( GOOS ) reported its second-quarter fiscal 2025 financial results before the market opened on Thursday. Here’s what you need to know. What To Know: Canada Goose reported second-quarter adjusted earnings per share of 5 cents, which may not compare to estimates for a loss of 4 cents. The company reported revenue of $267.8 million, beating...
Copyright 2023-2026 - www.financetom.com All Rights Reserved